On July 17, 2026 SL Science Holding Limited (NASDAQ: SLBT) ("SL Science" or the "Company"), a biotechnology company developing next-generation immune cell therapies, reported its successful exhibition and participation at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026) held at July 12-17, 2026 in Melbourne, Australia. Together with its esteemed academic and industry partners, the Company presented highly promising preclinical research on a novel treatment for glioblastoma (GBM), one of the most aggressive and difficult-to-treat forms of brain cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research showcased at the WCP 2026 exhibition is the result of a robust joint effort led by investigators at Taipei Medical University, in collaboration with SL Science, JY Biomedical Co., Ltd. ("JY BioMed") and HeXun Biosciences Co., Ltd.

Simplifying Complex Science for Real-World Impact

Glioblastoma is notoriously challenging to treat, often resisting conventional therapies such as surgery, radiation, and chemotherapy. Because tumors frequently return and build resistance, there is an urgent global need for innovative solutions. SL Science’s exhibition focused on harnessing gamma delta (γδ) T cells—a specialized subset of immune cells capable of identifying and attacking cancer cells without relying on the standard immune-matching processes that other therapies require.

The exhibited data revealed significant progress in overcoming tumor immune evasion. By delivering these specially expanded γδ T cells directly to the tumor site in preclinical models, researchers observed potent and efficient destruction of the brain cancer cells.

Key Exhibition Highlights

Complete Tumor Elimination: Direct administration of γδ T cells achieved complete eradication of the tumor by day 26 post-treatment at the highest dose tested (an 8:1 ratio of immune cells to cancer cells).
Dose-Dependent Success: The research demonstrated the feasibility and effectiveness of repeated direct-to-brain dosing, showing that the tumor-suppressing benefits scaled positively with the dosage.
Clean Safety Profile: Comprehensive health screens and blood panels confirmed that the treatment was well-tolerated in the study, showing no major safety concerns or adverse health effects.

"Exhibiting our collaborative work at WCP 2026 was a monumental milestone for our entire team and our partners," said Mr. William Wang, Chairman and Chief Executive Officer of SL Science. "We were thrilled to present these findings on a global stage. This research underscores the tremendous therapeutic potential of our γδ T-cell platform to combat challenging solid tumors like glioblastoma. By working closely with leading academic institutions, we are translating complex biology into tangible hope for patients facing high unmet medical needs."

(Press release, SL Science, JUL 17, 2026, View Source [SID1234669302])

On July 17, 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, reported three presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The three presentations will include:

Phase 1b data from anzu-cel, the Company’s lead PRAME cell therapy, in metastatic cutaneous and uveal melanoma, focusing on predictors of durable response
Phase 1 data from IMA203CD8 PRAME cell therapy across multiple PRAME-positive solid tumors, including durability follow-up at clinically relevant dose levels in gynecologic cancers, supporting the broad applicability of IMA203CD8 across diverse tumor types
Phase 1b data from IMA402, the Company’s PRAME bispecific, at recommended Phase 2 dose (RP2D) range across multiple cancers, supporting continued development in expansion cohorts and combination approaches

Collectively, these presentations highlight the breadth of Immatics’ PRAME franchise across two therapeutic modalities and a broad range of solid tumor indications.

Full abstracts will be published on the ESMO (Free ESMO Whitepaper) website on October 19, 2026, at 00:05 CEST.

Details on Oral and Poster Presentations

Title: Response durability with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy, in advanced melanoma
Presenting Author: Winfried Alsdorf, MD
Presentation Type: Poster presentation
Date / Time: October 24, 2026 / 12:00 – 12:45 CET
Presentation Number: 2128P

Title: Targeting PRAME+ Tumors with IMA203CD8, a PRAME-directed TCR T-cell Therapy: Results from a Phase 1 Study
Presenting Author: Antonia Busse, MD
Presentation Type: Proffered Paper presentation (oral presentation)
Session: Proffered paper: Investigational immunotherapy
Date / Time: October 23, 2026 / 13:30 – 15:00 CET
Presentation Number: 1946O

Title: Initial Results with IMA402 a PRAME-Targeted T-cell Receptor (TCR)-based Bispecific T-cell Engager (TCER) in Advanced Solid Tumors
Presenting Author: Dirk Schadendorf, MD
Presentation Type: Rapid Oral presentation
Session: Rapid oral: Investigational immunotherapy
Date / Time: October 24, 2026 / 08:30 – 10:00 CET
Presentation Number: 1955RO

About PRAME
PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.

(Press release, Immatics, JUL 17, 2026, View Source [SID1234669301])

On July 17, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported that its abstract titled "A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer" has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC) and will be presented by Dr. Nilofer Azad, MD, FASCO, Professor of Oncology, Associate Director of Clinical Research, Sidney Kimmel Cancer Center at Johns Hopkins University.

Presentation: Saturday, October 24, 2026
Session time: 10:15am – 11:45am CET

Additional details regarding the presentation will be made available in accordance with ESMO (Free ESMO Whitepaper) Congress policies.

(Press release, Compass Therapeutics, JUL 17, 2026, View Source [SID1234669300])

On July 17, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO (Free ESMO Whitepaper) plans to release further details for regular abstracts on October 19, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenter Abstract Title Presentation Details
Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 Abstract Number: 2396RO
Session Type: Rapid Oral presentation
Session Title: Rapid oral: NETs and endocrine tumours
Session Date: October 23, 2026
Session Time: 4:15 – 5:45pm CEST /
10:15 – 11:45am EDT
Presentation Time:
4:25 – 4:30pm CEST /
10:25 – 10:30am EDT
About [²¹²Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

(Press release, Perspective Therapeutics, JUL 17, 2026, View Source [SID1234669299])

On July 17, 2026 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, reported two presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral presentation at ESMO (Free ESMO Whitepaper)." said Julie Eastland, Chief Executive Officer. "The data will showcase the long-term survival benefits demonstrated by azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer in this study and further support our strategic focus on advancing azenosertib in registration-intended monotherapy trials for this biomarker-selected patient population with high unmet need."

Rapid oral presentation:
Title: "Azenosertib in platinum-resistant ovarian cancer (PROC): overall survival analysis from Part 1b of the DENALI study (GOG-3066)"
Date/Time: Friday, October 23, 2026, 4:15 p.m. – 5:45 p.m. CEST
Presentation Number: 1242RO

Trial-in-progress poster presentation:
Title: "ASPENOVA: A phase 3 study of azenosertib monotherapy versus standard of care chemotherapy in cyclin E1-positive platinum-resistant ovarian cancer (PROC)"
Date/Time: Monday, October 26, 2026, 12:00 p.m. – 12:45 p.m. CEST
Presentation Number: 1339TiP

About DENALI Clinical Trial
DENALI is a multi-part Phase 2 registration-intended clinical trial (NCT05128825) studying azenosertib in PROC patients.

Part 1b enrolled patients with PROC regardless of Cyclin E1 protein expression, all treated at 400mg QD 5:2 (5 days once-daily administration of azenosertib, followed by 2 days without azenosertib).

Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis’ proprietary immunohistochemistry cutoff. Part 2, in total, is designed to support accelerated approval, pending positive study outcomes and further discussions with the FDA. The study design consists of the following parts:

Part 2a: Dose confirmation evaluated two doses, 300mg QD 5:2 and 400mg QD 5:2, with approximately 30 patients enrolled per dose group. 400mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.
Part 2b: Enrollment expansion at the selected 400mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. This cohort is currently enrolling.
Part 2c: Broadening study population, which is expected to include approximately 40 patients previously treated with a taxane-containing regimen for PROC. This cohort is currently enrolling.

For physician and patient information about the DENALI trial, please visit www.denalitrial.com.

About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator’s choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). The trial design was based on feedback from the U.S. FDA regarding requirements for seeking approval under the accelerated approval pathway and requirements to support potential conversion to full approval.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

(Press release, Zentalis Pharmaceuticals, JUL 17, 2026, View Source [SID1234669298])